A similar study by Schmohl et al. demonstrated that EpCAM targeted TriKEs could improve NK cell expansion, ADCC and survival against EpCAM+ colorectal carcinoma cells in vitro [111]. The gene discussed is EPCAM; the disease is colorectal carcinoma.